Royalty Pharma plc (RPRX) SEC Filings & Earnings Calls

Alyftrek royalty dispute with Vertex

“Beginning in the second quarter of 2025, we did not receive from Vertex the full amount of royalty receipts on Alyftrek net sales to which we believe that we are contractually entitled.” · word for word

Concentration risk in cystic fibrosis franchise

“Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 30% and 32% of our current portion of financial royalty assets, respectively.” · word for word

Interest rate risk from floating-rate debt

“We are subject to interest rate fluctuations through any borrowings under our Revolving Credit Facility, Term Loan and through investments in money market accounts and marketable securities, the majority of which bear variable interest rates.” · word for word

Concentration in a few key products; Promacta declining due to generic competition.

“Promacta ... (75)% ... due to U.S. generic competition”

Foreign exchange impact could affect guidance; assumed +1% for remainder of year.

“estimated foreign exchange impact of approximately +1% to Portfolio Receipts” · word for word

Covenants require maintaining leverage ratio ≤4.0x and coverage ratio ≥2.5x, which could restrict financial flexibility.

“Covenants: consolidated leverage ratio ≤4.00:1.00, consolidated portfolio cash flow ratio ≤5.00:1.00, consolidated coverage ratio ≥2.50:1.00.”

Vertex royalty dispute

“Beginning in the second quarter of 2025, we did not receive from Vertex the full amount of royalty receipts on Alyftrek net sales to which we believe that we are contractually entitled.” · word for word

Tazverik impairment

“We recorded $69.4 million of non-cash impairment charges related to Tazverik following announcements by Ipsen and Eisai in March 2026 of the voluntary withdrawal of Tazverik across all indications and markets.”

Concentration risk

“Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31% and 32% of our current portion of financial royalty assets, respectively.” · word for word

Interest rate risk

“Interest expense increased by $28.5 million, or 43.6%, in the first quarter of 2026 as compared to the first quarter of 2025, primarily driven by the issuance of $2.0 billion of senior unsecured notes in September 2025 and the $380 million term loan.” · word for word

Guidance assumes no major adverse events or FX changes; excludes future transactions.

“This guidance assumes no major unforeseen adverse events or changes in foreign exchange rates and excludes the contributions from transactions announced subsequent to the date of this press release.” · word for word

Interest paid expected $350M-$360M; no additional debt assumed.

“Interest paid $350 million to $360 million; assumes no additional debt financing in 2026.” · word for word

Future funding and royalties depend on regulatory approval and commercial success of daraxonrasib.

“Additional $750 million in synthetic royalty funding available... following achievement of certain regulatory, commercial and clinical milestones.”

Concentration risk in biopharmaceutical royalties

“We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies” · word for word

Pledging of shares by executives

“Mr. Legorreta has pledged interests in the Private Holders exchangeable for 15,850,000 Class A ordinary shares pursuant to a pledge agreement to secure a loan made to Mr. Legorreta.” · word for word

Product concentration risk

“the top five product franchises accounted for 61% of our Royalty Receipts in the year ended December 31, 2025.” · word for word

Leverage and interest rate risk

“As of December 31, 2025, our total principal amount of our senior unsecured notes and borrowings under our term loan was $9.2 billion.” · word for word

Drug pricing regulatory risk

“initiatives toward 'most favored nation' (MFN) drug pricing in the United States could lead to decreased drug pricing or the drug pricing provisions of the Inflation Reduction Act” · word for word

Development-stage product failure risk

“We have previously acquired royalties on development-stage product candidates for which clinical development was stopped for a number of reasons, including clinical trials failing to meet their primary endpoints.” · word for word

Concentration risk in top products; Imbruvica -13%, Promacta -38% in Q4.

“Imbruvica declined 13% to $40M; Promacta declined 38% to $27M in Q4 2025.”

High debt level of $9.2B.

“Total debt with principal value of $9.2 billion.” · word for word

Concentration in a few key products.

“Top products include cystic fibrosis franchise, Trelegy, Tysabri, Evrysdi, Xtandi.”

High leverage and interest rate risk

“As of September 30, 2025, our total principal amount of indebtedness outstanding under our senior unsecured notes and term loan was $9.2 billion.” · word for word

Concentration risk in top products

“While our current asset portfolio includes royalties relating to over 35 marketed products, the top five product franchises accounted for 60% of our Royalty Receipts in the first nine months of 2025.” · word for word

Volatility in GAAP results due to effective interest method

“Over the course of the next 10 quarters, we recognized non-cash provision expense as a result of these changes in forecasts, including a non-cash expense of $743.2 million in 2016, ultimately reaching a peak cumulative allowance of $1.30 billion by September 30, 2017 related to this financial royalty asset.” · word for word